New Delhi, Apr 5 (ANI): The Modi government’s much touted campaign of ‘Make in India’ and the Department of Industrial Promotion and Policy’s (DIPP) efforts to push ‘Ease of doing Business’ has started paying dividends with Special Economic Zones (SEZs) becoming the most favorite investment destinations.
The latest among the recent investments is Gujarat based SEZ, which attracted Rs. 100 crore investment for a Pharma sector Research and Development Centre.
A state-of-the-art research and development centre ‘Navin Saxena Research and Technology'(NSRT), Clinical research organization, ‘Quest Care’ and a specialized manufacturing unit for transdermal patches was launched today at the Kandla SEZ.
The facility, owned by parent company Rusan Pharma Ltd, is the only one in the country to manufacture Nicotine transdermal patches in India. Set up in alignment with the PM’s ‘Make in India’ initiative, it is expected go a long way in making the Kandla SEZ vibrant and investor-friendly.
The new establishment at Kandla houses three subsidiaries, namely the Navin Saxena Research and Technology (NSRT) Centre, Quest Care, which is the company’s clinical research organization and Rusan’s dedicated Transdermal Patch Facility.
Together, these three units will handle the myriad aspects of addiction and pain management drug manufacture and export as a part of their portfolio, including research and innovation, licensing, IPR, patenting, quality assurance.
They offer immense employment opportunities not only to the local population but also to highly qualified scientists from India and abroad.
A senior official of DIPP said, “Things are moving forward and fast. The government is sensitive about the immediate requirements of the investors. For Pharma sector regulations and rules are being simplified and streamlined. An investor-friendly policy is already in place.”
NSRT is a dedicated research and development facility that has state-of-the-art technology and equipment. Research at NSRT will focus on pain, addiction, CNS and orphan diseases, drug delivery and platform technologies.
It has been set up with a vision to develop, register and license its new products to third parties. It also aims to undertake contract research and joint development projects.
Rusan group companies together have a current turnover of Rs. 300 crore and intend to grow to 600 crore in 2018. Being the first Indian company to do research on addiction and disease, they intend to expand their new facility with an investment of Rs. 100 crore in next year.
Dr. Navin Saxena, Chairman and Founder of Rusan Pharma Ltd, said, “With our continuous efforts and innovation we are proud to announce the biggest government and private Indian company deal between Brazil Health Ministry and Rusan Pharma Ltd. for USD 20 million per annum for their program for smoking cessation.”
To push collaborative research, a multi-party memorandum of understanding (MoU) was signed on the occasion between NSRT, Moscow State University (Russia), Symbiosis College Pune, the Maharaja Sayajirao University of Baroda and IIT Kanpur.
“The MoU highlights NSRT’s commitment to collaborative research. This would further flare up reverse brain drain for Indian students,” Dr Saxena said. (ANI)